Open-label, uncontrolled, before-and-after study of GGS in chronic inflammatory demyelinating polyneuropathy (CIDP) (Phase 3 study)
Phase of Trial: Phase III
Latest Information Update: 18 Jun 2018
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Therapeutic Use
- Sponsors Teijin Pharma
- 18 Jun 2018 Status changed from recruiting to completed.
- 01 May 2017 Planned End Date changed from 31 Mar 2016 to 30 Apr 2018.
- 08 Jun 2016 New trial record